| scholarly article | Q13442814 |
| P50 | author | Isabel Iriepa | Q56925426 |
| Manuela Bartolini | Q38802804 | ||
| Manuela López | Q39676372 | ||
| Javier Egea | Q41539393 | ||
| Ignacio Moraleda | Q48131084 | ||
| Vincenza Andrisano | Q56441574 | ||
| P2093 | author name string | Abdelouahid Samadi | |
| José Marco-Contelles | |||
| Marco Pistolozzi | |||
| Enrique Gálvez | |||
| P2860 | cites work | Specific Targeting of Acetylcholinesterase and Butyrylcholinesterase Recognition Sites. Rational Design of Novel, Selective, and Highly Potent Cholinesterase Inhibitors | Q58855822 |
| Heterodimeric Tacrine-Based Acetylcholinesterase Inhibitors: Investigating Ligand−Peripheral Site Interactions | Q59215340 | ||
| Effects of nicotinic receptor agonists on beta-amyloid beta-sheet formation | Q77407994 | ||
| Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase | Q80189214 | ||
| Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase | Q24561371 | ||
| A new and rapid colorimetric determination of acetylcholinesterase activity | Q26778487 | ||
| Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II | Q27627732 | ||
| Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products | Q27641694 | ||
| Recent advances in the Friedländer reaction | Q28240989 | ||
| Prazosin-Related Compounds. Effect of Transforming the Piperazinylquinazoline Moiety into an Aminomethyltetrahydroacridine System on the Affinity for α1-Adrenoreceptors | Q29036292 | ||
| Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability | Q29617252 | ||
| CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia | Q33239180 | ||
| N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure | Q33253112 | ||
| Treatment of Alzheimer's disease: current status and new perspectives. | Q35206995 | ||
| Dimeric and hybrid anti-Alzheimer drug candidates | Q36395551 | ||
| A century of Alzheimer's disease | Q36643414 | ||
| Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors | Q36653733 | ||
| Multi-target-directed ligands to combat neurodegenerative diseases | Q37052982 | ||
| Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease | Q37310651 | ||
| Effect of chirality of small molecule organofluorine inhibitors of amyloid self-assembly on inhibitor potency | Q37445917 | ||
| Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease | Q39859798 | ||
| Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors | Q40376638 | ||
| Both the D-(+) and L-(-) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity | Q40597988 | ||
| Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution | Q42153291 | ||
| Ligand-receptor interaction at the neural nicotinic acetylcholine binding site: a theoretical model. | Q44192976 | ||
| Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease | Q44215861 | ||
| beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies | Q44277892 | ||
| 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy | Q44457429 | ||
| A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease | Q44586144 | ||
| Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action | Q46799165 | ||
| Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. | Q46898998 | ||
| First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor. | Q46943887 | ||
| A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques. | Q48456115 | ||
| Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds | Q48491553 | ||
| Brain acetylcholinesterase promotes amyloid-beta-peptide aggregation but does not hydrolyze amyloid precursor protein peptides | Q48527315 | ||
| Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. | Q49047282 | ||
| Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. | Q53283675 | ||
| A small molecule targeting the multifactorial nature of Alzheimer's disease. | Q53285864 | ||
| Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. | Q53290732 | ||
| CHARMM: A program for macromolecular energy, minimization, and dynamics calculations | Q53340989 | ||
| Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. | Q53391276 | ||
| P433 | issue | 11 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| enantiomer | Q494483 | ||
| P304 | page(s) | 1990-1997 | |
| P577 | publication date | 2011-08-24 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | Chemical and pharmacological studies on enantiomerically pure p-methoxytacripyrines, promising multi-target-directed ligands for the treatment of Alzheimer's disease | |
| P478 | volume | 6 |
| Q56960330 | 5-Methyl--(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5-indolo[2,3-]quinolin-11-amine: a highly potent human cholinesterase inhibitor |
| Q45368696 | Enantioselective neuroprotective effects of Tacripyrine ITH122 against oxygen and glucose deprivation in rat hippocampal slices |
| Q37559812 | Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease |
| Q34165015 | Structure-activity relationships of organofluorine inhibitors of β-amyloid self-assembly |
| Q59807620 | Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapy |
| Q39199947 | Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-induced neurotoxicity. |
Search more.